The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CADL | -41.18% | N/A | N/A | -29% |
| S&P | +20.12% | +68.19% | +10.95% | +51% |
Candel Therapeutics, Inc. is a late clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$163.00K | 33.5% |
| Market Cap | $310.18M | -19.7% |
| Market Cap / Employee | $5.64M | 0.0% |
| Employees | 55 | 44.7% |
| Net Income | -$29,496.00K | -109.6% |
| EBITDA | -$15,589.00K | -97.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $119.73M | 16.6% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $48.59M | 1514.3% |
| Short Term Debt | $445.00K | -95.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -32.81% | 41.3% |
| Return On Invested Capital | -75.13% | -11.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10,977.00K | -88.7% |
| Operating Free Cash Flow | -$10,568.00K | -81.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.00 | 3.34 | 3.10 | 3.87 | -121.18% |
| Price to Tangible Book Value | 4.00 | 3.34 | 3.10 | 3.87 | -121.18% |
| Enterprise Value to EBITDA | -28.94 | -15.38 | -15.39 | -15.36 | -44.74% |
| Return on Equity | -98.1% | -55.2% | -70.2% | -64.6% | -53.73% |
| Total Debt | $10.91M | $8.34M | $7.21M | $49.03M | 264.00% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
